UBS Group Reiterates Buy Rating for Roche Holdings AG Basel (OTCMKTS:RHHBY)

UBS Group reiterated their buy rating on shares of Roche Holdings AG Basel (OTCMKTS:RHHBY) in a research note issued to investors on Wednesday morning, The Fly reports.

Several other research analysts have also issued reports on the company. Sanford C. Bernstein assumed coverage on Roche Holdings AG Basel in a research report on Monday, July 13th. They issued an outperform rating on the stock. Barclays restated an overweight rating on shares of Roche Holdings AG Basel in a research report on Friday, May 15th. Morgan Stanley reiterated an overweight rating on shares of Roche Holdings AG Basel in a report on Wednesday. AlphaValue upgraded Roche Holdings AG Basel to a reduce rating in a report on Friday, July 3rd. Finally, HSBC upgraded Roche Holdings AG Basel from a reduce rating to a hold rating in a report on Thursday, April 30th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus target price of $48.00.

OTCMKTS RHHBY opened at $43.10 on Wednesday. Roche Holdings AG Basel has a 52 week low of $33.30 and a 52 week high of $46.63. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.04 and a current ratio of 1.30. The stock has a market capitalization of $295.17 billion, a P/E ratio of 16.97, a price-to-earnings-growth ratio of 3.01 and a beta of 0.37. The stock has a fifty day moving average of $44.21 and a 200-day moving average of $42.63.

Several institutional investors and hedge funds have recently added to or reduced their stakes in RHHBY. Park National Corp OH acquired a new stake in shares of Roche Holdings AG Basel in the 1st quarter valued at about $5,526,000. S&T Bank PA acquired a new stake in shares of Roche Holdings AG Basel in the first quarter valued at about $3,988,000. Douglass Winthrop Advisors LLC increased its position in Roche Holdings AG Basel by 6.8% during the second quarter. Douglass Winthrop Advisors LLC now owns 852,236 shares of the company’s stock worth $36,970,000 after buying an additional 54,187 shares during the last quarter. Jolley Asset Management LLC acquired a new position in Roche Holdings AG Basel during the first quarter worth approximately $2,012,000. Finally, Cypress Asset Management Inc. TX acquired a new position in Roche Holdings AG Basel during the second quarter worth approximately $1,294,000. 0.30% of the stock is currently owned by hedge funds and other institutional investors.

Roche Holdings AG Basel Company Profile

Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.

Recommended Story: How a Back-End Load Mutual Fund Works

The Fly

Analyst Recommendations for Roche Holdings AG Basel (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.